Max Robotics — Global Service Robot Directory + US Certification

About

Naotaka Kumada is a urologic surgeon and researcher whose work focuses on advancing treatment strategies for high-risk and very-high-risk prostate cancer, as well as refining surgical training for complex robotic procedures. His major contributions center on the development and evaluation of neoadjuvant chemohormonal therapy—combining luteinizing hormone-releasing hormone antagonists with tegafur-uracil—prior to robot-assisted radical prostatectomy. This work, published in 2023, has garnered 9 citations and provides critical evidence on biochemical recurrence outcomes in very-high-risk patients. Additionally, his 2023 study on the efficacy and safety of this neoadjuvant regimen (5 citations) offers a detailed retrospective analysis that supports its use as a viable treatment pathway. Beyond oncology, Kumada has innovated surgical education through the “Trisection Method” for robot-assisted radical cystectomy, a training system that divides the procedure into three focused parts to enhance surgeon concentration, reduce fatigue, and mentor young surgeons in Japan. His research, though early in citation impact, addresses pressing clinical needs and educational gaps, positioning him as a rising contributor to urologic oncology and robotic surgery training.